Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Outcomes with Single Agent LIPO-DOX in Platinum-Resistant Ovarian and Fallopian Tube Cancers and Primary Peritoneal Adenocarcinoma - Chiang Mai University Hospital Experience

  • Published : 2014.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Single pegylated liposomal doxorubicin (PLD) is commonly used as a salvage treatment in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma (PPA) with a satisfactory outcome. However, the data for second generation PLD administered in this setting are still limited. We conducted a retrospective study to evaluate the outcome of patients who received single-agent second generation PLD (LIPO-DOX) after the development of clinical platinum resistance. The study period was between March 2008 and March 2013. LIPO-DOX was administered intravenously 40 $mg/m^2$ every 28 days until disease progression, but for not more than six cycles. The response rate was evaluated using the Gynecologic Cancer Intergroup (GCIG) criteria while the toxicity was evaluated according to WHO criteria. Twenty-nine patients met the inclusion criteria in the study period with an overall response rate of 13.8%. The median progression free survival and overall survival were three and eleven months, respectively. With the total of 96 cycles of chemotherapy, the patients developed grades 3 and 4 hematologic toxicity as follows: anemia, 0%, leukopenia, 9.6%, neutropenia, 32.3% and thrombocytopenia, 0%. In conclusion, the single agent second generation PLD demonstrated modest efficacy in patients with platinum-resistant ovarian cancer, fallopian tube cancer and PPA without serious toxicity.

Keywords

References

  1. Bast RC Jr, Markman M (2010). Chemotherapy: A new standard combination for recurrent ovarian cancer? Nat Rev Clin Oncol, 7, 559-60. https://doi.org/10.1038/nrclinonc.2010.152
  2. Ferrandina G, Ludovisi M, Lorusso D, et al (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol, 26, 890-6. https://doi.org/10.1200/JCO.2007.13.6606
  3. Gordon AN, Granai CO, Rose PG, et al(2000). Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol, 18, 3093-100.
  4. Hsiao SM, Chen CA, Lin HH, et al (2009). Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. Gynecol Oncol, 112, 35-9. https://doi.org/10.1016/j.ygyno.2008.09.033
  5. Khemapech N, Oranratanaphan S, Termrungruanglert W, et al (2013). Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox$^{(R)}$). Asian Pac J Cancer Prev, 14, 2131-5. https://doi.org/10.7314/APJCP.2013.14.3.2131
  6. Markman M (2011). Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res, 3, 219-25.
  7. Mutch DG, Orlando M, Goss T, et al (2007). Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol, 25, 2811-8. https://doi.org/10.1200/JCO.2006.09.6735
  8. Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
  9. Naumann RW, Coleman RL (2011). Management strategies for recurrent platinum-resistant ovarian cancer. Drugs, 71, 1397-412. https://doi.org/10.2165/11591720-000000000-00000
  10. Pectasides D, Psyrri A, Pectasides M, et al (2006). Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? Expert Opin Pharmacother, 7, 75-87.
  11. Rustin GJ, Vergote I, Eisenhauer E, et al (2011). Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer, 21, 419-23. https://doi.org/10.1097/IGC.0b013e3182070f17
  12. Taiwanese Gynecologic Oncology Group, Chou HH, Wang KL, et al (2006). Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with longterm follow-up. Gynecol Oncol, 101, 423-8. https://doi.org/10.1016/j.ygyno.2005.10.027

Cited by

  1. Radiotherapy for Ovarian Cancers - Redefining the Role vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4759
  2. Treatment Outcomes of Gemcitabine in Refractory or Recurrent Epithelial Ovarian Cancer Patients vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5215
  3. Intra-Peritoneal Cisplatin Combined with Intravenous Paclitaxel in Optimally Debulked Stage 3 Ovarian Cancer Patients: An Izmir Oncology Group Study vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6165
  4. Survival Outcomes of Recurrent Epithelial Ovarian Cancer: Experience from a Thailand Northern Tertiary Care Center vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10837
  5. Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer vol.28, pp.8, 2018, https://doi.org/10.1097/IGC.0000000000001324